文献速递肺血管病与心包/心肌炎

纳米颗粒递送STAT3缓解肺泡毛细血管发育不良小鼠模型中的肺动脉高压

Nanoparticle Delivery of STAT3 Alleviates Pulmonary Hypertension in a Mouse Model of Alveolar Capillary Dysplasia.
PubMed 文献 · Circulation · 2021-06-11

本研究在携带Foxf1 S52F突变(模拟ACDMPV患者)的小鼠中探究新生儿肺血管生成是否能预防肺动脉高压(PH)和右心室肥厚。结果显示Foxf1WT/S52F小鼠出生后发生PH和右心室肥厚,严重程度与死亡率等相关;血管内递送携带Stat3 cDNA的纳米颗粒可保护小鼠免于右心室肥厚和PH,改善生存并减少肺纤维化重塑。

要点

  • Foxf1WT/S52F小鼠出生后出现PH和右心室肥厚。
  • PH严重程度与死亡率、低体重等相关。
  • 纳米颗粒递送Stat3可预防PH和右心室肥厚。

核心结论

  • 纳米颗粒疗法增加新生儿肺血管生成可能用于预防ACDMPV中的PH。

研究设计与样本

  • 使用Foxf1WT/S52F小鼠(携带ACDMPV患者中鉴定的S52F Foxf1突变)进行超声心动图、右心室导管术、免疫染色和生化方法检查。
  • 通过囊胚互补实验检验Foxf1WT/S52F突变胚胎干细胞在体内分化为呼吸细胞谱系的能力。
  • 采用血管内递送携带非整合Stat3表达载体的纳米颗粒改善新生小鼠肺血管生成。

主要发现

  • Foxf1WT/S52F小鼠出生后发生PH和右心室肥厚。
  • Foxf1WT/S52F小鼠PH严重程度直接与死亡率、低体重、肺动脉肌化及肺组织胶原沉积增加相关。
  • 人ACDMPV肺组织中发现纤维化重塑增加。
  • Foxf1WT/S52F胚胎干细胞倾向于分化为肺肌成纤维细胞。
  • 血管内递送携带Stat3 cDNA的纳米颗粒保护Foxf1WT/S52F小鼠免于右心室肥厚和PH,改善生存并减少肺纤维化重塑。

关键数值与推荐

  • Foxf1WT/S52F小鼠PH严重程度与死亡率、低体重、肺动脉肌化及胶原沉积增加相关。

临床怎么用

  • 纳米颗粒疗法增加新生儿肺血管生成可能考虑用于预防ACDMPV患者的PH。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pulmonary hypertension (PH) is a common complication in patients with alveolar capillary dysplasia with misalignment of pulmonary veins (ACDMPV), a severe congenital disorder associated with mutations in the FOXF1 gene. Although the loss of alveolar microvasculature causes PH in patients with ACDMPV, it is unknown whether increasing neonatal lung angiogenesis could prevent PH and right ventricular (RV) hypertrophy. METHODS: We used echocardiography, RV catheterization, immunostaining, and biochemical methods to examine lung and heart remodeling and RV output in Foxf1WT/S52F mice carrying the S52F Foxf1 mutation (identified in patients with ACDMPV). The ability of Foxf1WT/S52F mutant embryonic stem cells to differentiate into respiratory cell lineages in vivo was examined using blastocyst complementation. Intravascular delivery of nanoparticles with a nonintegrating Stat3 expression vector was used to improve neonatal pulmonary angiogenesis in Foxf1WT/S52F mice and determine its effects on PH and RV hypertrophy. RESULTS: Foxf1WT/S52F mice developed PH and RV hypertrophy after birth. The severity of PH in Foxf1WT/S52F mice directly correlated with mortality, low body weight, pulmonary artery muscularization, and increased collagen deposition in the lung tissue. Increased fibrotic remodeling was found in human ACDMPV lungs. Mouse embryonic stem cells carrying the S52F Foxf1 mutation were used to produce chimeras through blastocyst complementation and to demonstrate that Foxf1WT/S52F embryonic stem cells have a propensity to differentiate into pulmonary myofibroblasts. Intravascular delivery of nanoparticles carrying Stat3 cDNA protected Foxf1WT/S52F mice from RV hypertrophy and PH, improved survival, and decreased fibrotic lung remodeling. CONCLUSIONS: Nanoparticle therapies increasing neonatal pulmonary angiogenesis may be considered to prevent PH in ACDMPV.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Sun F, Wang G, Pradhan A, et al. Nanoparticle Delivery of STAT3 Alleviates Pulmonary Hypertension in a Mouse Model of Alveolar Capillary Dysplasia. Circulation. 2021. PMID: 34111939. doi:10.1161/CIRCULATIONAHA.121.053980

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。